Soleno Therapeutics/$SLNO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Soleno Therapeutics

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

Ticker

$SLNO
Sector
Health Care
Primary listing
NASDAQ

Industry

Biotechnology
Headquarters
Redwood City, United States

Employees

115

ISIN

US8342033094
Website
soleno.life

SLNO Metrics

BasicAdvanced
$4.2B
-
-$4.65
-2.67
-

Bulls say / Bears say

Soleno Therapeutics' DCCR (diazoxide choline) extended-release tablets have received Breakthrough Therapy Designation from the U.S. FDA for treating Prader-Willi syndrome, potentially expediting the drug's approval process. (GlobeNewswire)
The company maintains a strong cash position of $284.7 million as of Q3 2024, providing substantial resources for ongoing research and development. (StockTitan)
Positive clinical trial results for DCCR have demonstrated significant reductions in hyperphagia and improvements in behavioral domains for Prader-Willi syndrome patients, enhancing the drug's market potential. (StockTitan)
The FDA has extended the review period for DCCR by three months to March 27, 2025, potentially delaying the drug's market entry. (StockTitan)
Operating expenses have surged, with R&D expenses reaching $30.1 million and G&A expenses at $49.2 million in Q3 2024, leading to a net loss of $76.6 million for the quarter. (StockTitan)
The company has a history of shareholder dilution, with recent funding rounds potentially impacting existing shareholders' value. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.

SLNO News

AllArticlesVideos
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference

Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference

GlobeNewsWire·2 weeks ago
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome

Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome

GlobeNewsWire·1 month ago
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome

Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome

GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SLNO

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs